Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.
Alessandra MangiaScott MilliganMandana KhaliliStefano FagiuoliStephen D ShafranFabrice CarratDenis OuzanGeorgios PapatheodoridisAlnoor RamjiSergio M BorgiaHeiner WedemeyerRuggero LosappioFrancisco Pérez-HernandezNicole WickRobert S BrownPietro LamperticoKaren DoucetteIoanna NtallaHeribert RamrothMichael MertensKim VanstraelenJuan TurnesPublished in: Liver international : official journal of the International Association for the Study of the Liver (2020)
In this large cohort, representative of clinical practice, a simple 12-week regimen of SOF/VEL without ribavirin resulted in high SVR12/24 rates in diverse patient populations, even among those with compensated cirrhosis.